论文部分内容阅读
目的 :探讨米索前列醇用于足月妊娠引产的安全性。方法 :回顾性分析了 2 16例使用米索前列醇引产和 2 0 0例使用缩宫素引产的足月妊娠产妇的临床资料。结果 :米索组产程中出现不协调宫缩 6 3例 ,占 2 9.2 % ,过频宫缩 43例 ,占 19.9% ,而缩宫素未出现异常宫缩。两组羊水混浊发生率分别为 2 1.8%和 14.5 % ,P<0 .0 1,差异有显著性。两组 CST(+)发生率分别为 12 .0 %和 6 .0 % ,P<0 .0 5 ,差异有显著性。剖宫产原因中 ,胎儿宫内窘迫均为两组主要手术指征 ,米索组 30例 ,占 78.9% ,缩宫素 17例 ,占 5 4.8% ,P<0 .0 5 ,差异有显著性 ,提示 :米索前列醇用于足月妊娠引产 ,对母亲和胎儿有潜在的不安全因素存在
Objective: To investigate the safety of misoprostol in induction of labor during term pregnancy. Methods: A retrospective analysis of 216 cases of misoprostol induction of labor and 200 cases of oxytocin using full-term pregnancy induced oxytocin clinical data. Results: In the misoprostol group, 63 cases were uncoordinated contractions, accounting for 2 9.2%, 43 cases were over frequency contractions, accounting for 19.9%, while oxytocin had no abnormal contractions. The incidence of amniotic fluid opacity was 2 1.8% and 14.5% in both groups, P <0.01, the difference was significant. The incidence of CST (+) in both groups was 12.0% and 6.0% respectively, P <0.05, the difference was significant. Cesarean causes, fetal distress are two major indications for surgery, misoprostol 30 cases, accounting for 78.9%, oxytocin 17 cases, accounting for 4.8%, P <0.05, the difference was significant Sexuality, Tip: Misoprostol for term pregnancy induction, there are potential insecurity for mothers and fetuses